BRAF and neoplasm: Overall, our single CTC data revealed high genomic intra- and inter-patient genomic diversity in MAPK, MAPK-related and MAPK-independent pathways at resistance to BRAF inhibition, which was missed by bulk analyses on tumour biopsies and cfDNA.